KPIs & Operating Metrics(New)
Balance Sheet
Accounts PayablesAccumulated ExpensesAssetsCapital LeasesCash & Current InvestmentsCash & EquivalentsCommon EquityCurrent AssetsCurrent LeasesGoodwillGoodwill & IntangiblesInventoryLiabilities and Shareholders EquityLong-Term InvestmentsNon-Current AssetsNon-Current DebtNon-Current Deferred Tax LiabilityOperating LeasesOther Accumulated ExpensesOther Non-Current AssetsOther Non-Current LiabilitiesPayablesPrepaid AssetsProperty, Plant & Equipment (Net)ReceivablesRetained EarningsShareholder's EquityShares OutstandingShort term DebtShort-term InvestmentsTotal Current LiabilitiesTotal DebtTotal LiabilitiesTotal Non-Current LiabilitiesTreasury Shares
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Castle Biosciences (CSTL) Prepaid Assets (2018 - 2025)

Castle Biosciences' Prepaid Assets history spans 7 years, with the latest figure at $8.0 million for Q4 2025.

  • For Q4 2025, Prepaid Assets rose 3.72% year-over-year to $8.0 million; the TTM value through Dec 2025 reached $8.0 million, up 3.72%, while the annual FY2025 figure was $8.0 million, 3.72% up from the prior year.
  • Prepaid Assets for Q4 2025 was $8.0 million at Castle Biosciences, down from $11.9 million in the prior quarter.
  • Across five years, Prepaid Assets topped out at $12.1 million in Q2 2025 and bottomed at $3.1 million in Q1 2021.
  • The 5-year median for Prepaid Assets is $6.5 million (2023), against an average of $6.9 million.
  • The largest annual shift saw Prepaid Assets skyrocketed 99.13% in 2021 before it fell 8.47% in 2024.
  • A 5-year view of Prepaid Assets shows it stood at $4.8 million in 2021, then increased by 29.12% to $6.2 million in 2022, then grew by 1.37% to $6.3 million in 2023, then increased by 21.92% to $7.7 million in 2024, then grew by 3.72% to $8.0 million in 2025.
  • Per Business Quant, the three most recent readings for CSTL's Prepaid Assets are $8.0 million (Q4 2025), $11.9 million (Q3 2025), and $12.1 million (Q2 2025).